Multi-Step Chromatography for rAAV Purification

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current scalable purification processes for recombinant adeno-associated virus (rAAV) vectors fail to adequately remove impurities, leading to inconsistent vector purity, potency, and safety, which is crucial for clinical applications, due to the challenges in distinguishing and separating rAAV from co-released cellular proteins and nucleic acids during production.

Innovation Solution

A multi-step chromatography process involving anion and cation exchange column chromatography, combined with size exclusion chromatography, is employed to purify rAAV vectors, reducing contaminating nucleic acids and protein impurities, and concentrating the vectors to achieve higher purity levels.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If transient transfection process using three plasmids is used to produce rAAV vectors, then productivity is improved, but manufacturing precision deteriorates due to significant amounts of plasmid DNA and cellular proteins/nucleic acids being co-released

Engineering Contradiction:

ImproverAAV vector production efficiencyVSAvoidrAAV vector purity

Core Design Contradiction:

ProductivityVSManufacturing precision

Solution Approach 1:

The purification process is divided into multiple sequential chromatography steps (anion exchange, cation exchange, and size exclusion) that separately target different impurity types. Each step segments the purification task, removing specific classes of contaminants (plasmid DNA, cellular proteins, nucleic acids) to achieve cumulative purification效果

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

Chromatography media serve as intermediary substances that selectively bind to different impurities. The anion exchange media binds plasmid DNA, cation exchange media binds cellular proteins, and size exclusion media separates based on molecular size, allowing indirect removal of contaminants while preserving rAAV vectors

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of manufacture

If current scalable purification processes are used, then ease of manufacture is improved, but manufacturing precision deteriorates leading to inconsistent vector purity, potency and safety

Engineering Contradiction:

Improvepurification process scalabilityVSAvoidvector purity consistency

Core Design Contradiction:

Ease of manufactureVSManufacturing precision

Solution Approach 1:

The process optimizes multiple parameters including pH gradients during chromatography elution, flow rates through each column, and buffer compositions to maximize purification efficiency. These parameter changes ensure consistent separation of rAAV from impurities across different production scales

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The multi-step chromatography process operates continuously without interruption, with each purification step seamlessly transitioning to the next. This continuous action prevents re-contamination and maintains consistent purification quality throughout the manufacturing process

Inventive Principle:

Principle #20Continuity of useful action

3Productivity

If rAAV vectors are produced by transient transfection with three plasmids, then productivity is improved, but object-generated harmful factors increase due to co-release of cellular proteins and nucleic acids

Engineering Contradiction:

ImproverAAV vector yieldVSAvoidcontaminating impurities

Core Design Contradiction:

ProductivityVSObject-generated harmful factors

Solution Approach 1:

The process converts the harmful co-release of cellular components into a beneficial separation opportunity. By exploiting the different biochemical properties (charge, size) of impurities versus rAAV vectors, the chromatography steps transform the contamination problem into a series of selective binding and elution events that remove harmful factors

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method recovers approximately 40-70% of rAAV vector particles with enhanced purity compared to industry-standard methods, achieving greater than 100 mg/mL concentration and 1015 particles per mL, significantly improving the consistency and safety of rAAV vectors for clinical use.

Implementation Method 1

subjecting the clarified lysate or diluted clarified lysate produced in step (e) to anion or cation exchange column chromatography to produce a column eluate comprised of rAAV vector particles

Methodology Applied

Scientific EffectIon Exchange: Ion Exchange

Implementation Method 2

subjecting the second column eluate or the diluted second column eluate produced in step (g) to cation or anion exchange column chromatography to produce a third column eluate comprised of rAAV vector particles thereby separating rAAV vector particles from protein or other production impurities

Methodology Applied

Scientific EffectIon Exchange: Ion Exchange

Implementation Method 3

subjecting the column eluate or the concentrated column eluate produced in step (f) to size exclusion column chromatography to produce a second column eluate comprised of rAAV vector particles, thereby separating rAAV vector particles from protein impurities

Methodology Applied

Scientific EffectChromatography: Chromatography

Data Source

PatentUS11702639B2Column-based fully scalable rAAV manufacturing process

Publication Date: 2023.07.18 SPARK THERAPEUTICS INC

AI summary

In accordance with the invention, provided herein are methods for purifying recombinant adeno-associated (rAAV) vector particles.